GlassScriptPhysician profile
Misty Dawn Shields
NPI 1699120824
$39,276.87
in general payments reported to CMS, 2019-2025
19 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,845 · 2023: $22K · 2024: $1,057 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $15K · Travel and Lodging: $3,347 · Food and Beverage: $3,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,290.00 |
| Consulting Fee | $14,672.50 |
| Travel and Lodging | $3,347.06 |
| Food and Beverage | $3,122.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21,858.36 | 2022-2025 | Zepzelca |
| Astrazeneca Pharmaceuticals LP | $11,988.43 | 2023-2025 | Imfinzi |
| Astrazeneca Uk Limited | $4,020.00 | 2025 | Imfinzi |
| Pharmacosmos Therapeutics INC. | $478.73 | 2024 | Cosela |
| Genentech USA, INC. | $429.74 | 2023-2025 | Tecentriq, Alecensa, Rozlytrek |
| Medtronic, INC. | $143.33 | 2024 | Signia |
| Seagen INC. | $99.95 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $56.79 | 2024 | |
| Daiichi Sankyo INC. | $49.75 | 2025 | Enhertu |
| Genentech, INC. | $38.48 | 2023 | Alecensa, Gavreto, Avastin |
| G1 Therapeutics, INC. | $24.46 | 2023 | Cosela |
| Regeneron Pharmaceuticals, INC. | $23.88 | 2023 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $23.43 | 2023 | Opdivo |
| Amgen INC. | $21.18 | 2023 | |
| Janssen Biotech, INC. | $20.36 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.